1 active not recruiting, 1 completed, 1 unknown. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
Follow SHINGRIX®: new trials by email Literature Review of SHINGRIX® trials Research Report on SHINGRIX®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Recombinant Herpes Zoster Vaccine (RZV), MTX Discontinuation, MMF Discontinuation - Rheumatoid Arthritis, Spondylitis, Ankylosing | Phase 4 | Active not recruiting | University of Sao Paulo General Hospital | 2005 | 2023-05-23 | 2026-05-04 |
| Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients recombinant zoster vaccine - Shingles, Zoster | Phase 4 | Unknown | Prof Patrice Lalive | 100 | 2022-12-01 | 2024-04-10 |
| Simultaneous RZV and aIIV4 Vaccination FLUAD® Quadrivalent, Fluzone® High-Dose Quadrivalent, SHINGRIX® - Pain, Quality of Life | Phase 4 | Completed | Duke University | 267 | 2021-09-21 | 2024-07-11 |
Herpes Zoster (2) · Arthritis, Juvenile (1) · Arthritis, Rheumatoid (1) · Behcet Syndrome (1) · Dermatomyositis (1) · Drug-Related Side Effects and Adverse Reactions (1) · Influenza, Human (1) · Injection Site Reaction (1) · Lupus Erythematosus, Systemic (1) · Multiple Sclerosis (1) · Myositis (1) · Pain (1) · Scleroderma, Systemic (1) · Sjogren's Syndrome (1) · Spondylarthritis (1)
Duke University (1) · Prof Patrice Lalive (1) · University of Sao Paulo General Hospital (1)
Brazil (1) · Switzerland (1) · United States (1)
Arnaud Didierlaurent, Pr (1) · Kenneth Schmader, MD (1) · Patrice Lalive, Pr (1)
PMID 37781954, PMID 39446325, PMID 41679320, PMID 41932224, PMID 42261247, PMID 42294825, PMID 42843284